Reeves plans increase in capital gains tax on shares: Report
Reeves is expected to maintain the current capital gains tax rate on second homes and buy-to-let properties.
By EasternEYeOct 17, 2024
RACHEL Reeves is expected to raise the capital gains tax rate on the sale of shares and other assets in her budget statement on 30 October. The increase for share sales is likely to be by several percentage points.
Alongside this, Reeves is anticipated to end certain reliefs in the current capital gains tax regime to boost revenues, aiming to improve public finances and avoid austerity, The Times reported on Wednesday.
While the report did not specify sources, it said that the capital gains tax on the sale of second homes would remain unchanged. However, some reliefs under the current regime are expected to be reduced to help raise more revenue.
The chancellor is expected to maintain the current capital gains tax rate on second homes and buy-to-let properties, with concerns that raising this rate could have negative financial consequences.
Currently, capital gains tax applies to profits exceeding £3,000 from the sale of assets, though self-invested personal pensions (SIPPs) and ISAs are exempt. According to The Times, there are about 12.5 million private shareholders, but only 350,000 pay this tax annually.
As the first Labour budget since the party's election in July, the October statement is under close scrutiny. It is expected to reveal who will face higher taxes and where spending cuts may be made to address the country’s financial challenges, which Labour attributes to the previous government.
Earlier, two government sources told Reuters that Reeves is considering tax rises and spending cuts worth £40 billion as part of efforts to stabilise the economy while investing in public services.
The current capital gains tax rate for higher-income taxpayers ranges between 20 per cent and 28 per cent, depending on the type of asset. For share sales, the rate is 20 per cent.
Keir Starmer, earlier this week, dismissed speculation that the capital gains tax rate would rise to 39 per cent, calling such reports unfounded.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.